A study is currently underway to assess the efficacy of intensifying HF treatment under pulmonary ultrasound guidance in the era of pharmacotherapy with SGLT-2 inhibitors (sodium–glucose cotransporter-2 inhibitors) and ARNI (angiotensin receptor blocker–neprilysin inhibitors) [40]. This evidence concerns the gene SLC5A2 and hydrops fetalis.